Cataract

MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE

Retrieved on: 
Wednesday, May 1, 2024
Glaucoma surgery, Sale, University, Moran Eye Center, Lecture, TGT, Refractive surgery, Hospital, Safety, Research, Cataract, Paratriathlon, IOP, Manchester Royal Eye Hospital, NCT, Biomaterial, ASCRS, Intraocular pressure, Patient, Society, Physician, ICGS, EGS, Glaucoma, Trabeculectomy, Moorfields Eye Hospital, ARVO, Medical device

Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.

Key Points: 
  • Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.
  • The Calibreye shunt is designed to deliver an adjustable solution to control IOP in patients requiring low IOP.
  • While these devices have demonstrated an improvement in complication rates, achieving the IOP reductions necessary for these glaucoma patients remains challenging.
  • The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is for investigational use only and is not for sale in the U.S. or outside the U.S.

Eye health survey uncovers Canadians' concerns about recent symptoms affecting their eyes & vision: Canadian Ophthalmological Society

Retrieved on: 
Wednesday, May 1, 2024
Education, AMD, Vance DeGeneres, Cataract, Sport, Diabetic retinopathy, Diabetes, Artificial intelligence, Eye, Screen time, Paratriathlon, Hockey, Eye injury, Glaucoma, Agriculture

TORONTO, May 1, 2024 /CNW/ - In time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness, understanding, and concerns around eye and vision health.

Key Points: 
  • TORONTO, May 1, 2024 /CNW/ - In time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness, understanding, and concerns around eye and vision health.
  • Of the four leading eye diseases affecting vision, cataracts and glaucoma are still the most commonly known among Canadians.
  • "While the survey reveals increased awareness, it also highlights significant concerns and alarming symptoms experienced by Canadians over the past two years, emphasizing the necessity for comprehensive eye health education and regular eye exams."
  • To learn more about the four major eye diseases and get information on overall eye health, visit seethepossibilities.ca.

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Retrieved on: 
Thursday, May 2, 2024
FDA, Hydrus, MIGS, Telecanthus, Nature, Refractive surgery, News, Research, Depreciation, Cataract, Security (finance), IOP, DED, Webcast, Growth, Environment, District court, Patent, Intraocular pressure, Patient, Court, Society, Judgement, Glaucoma, Alcon, Ciclosporin, Standard of care, GAAP, Pharmaceutical industry

Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.

Key Points: 
  • Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.
  • The jury found that Sight Sciences’ asserted patents were willfully infringed, and awarded monetary damages for past infringement.
  • Sight Sciences reaffirms revenue guidance expectations for full year 2024 of approximately $81.0 million to $85.0 million, representing growth of approximately 0% to 5% growth compared to 2023.
  • Sight Sciences' management team will host a conference call today, May 2, 2024, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.

Retrieved on: 
Tuesday, April 16, 2024
Stanford University, FDA, Johns Hopkins University, University, Oxidative stress, Investment, Retinitis pigmentosa, OIS, Publication, Epidemiology, Statistics, Biomedical engineering, Pfizer, Biomedicine, Therapy, Senior, MPH, Acquisition, Cataract, Ophthalmology, Partnership, Management

“We’re thrilled to welcome Dr. Cunningham to our board of directors,” said Halden Conner, Chairman, CEO and Co-Founder of Nacuity Pharmaceuticals.

Key Points: 
  • “We’re thrilled to welcome Dr. Cunningham to our board of directors,” said Halden Conner, Chairman, CEO and Co-Founder of Nacuity Pharmaceuticals.
  • He is also an internationally recognized specialist in infectious and inflammatory eye disease with over 400 publications.
  • “Nacuity’s approach to treating ophthalmic and non-ophthalmic disorders is both completely novel and tremendously promising,” said Dr. Cunningham.
  • Dr. Cunningham is a member of the board of directors of Galera Therapeutics and Executive Chairman of Eyconis.

LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Retrieved on: 
Thursday, May 2, 2024
Health, Medical Devices, Technology, Surgery, Health Technology, Software, Optical, Domestic, International, Telephone, Webcast, Cataract

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024.

Key Points: 
  • LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024.
  • LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights.
  • To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com .
  • Following the live webcast, an archived version of the call will be available on the website.

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Wednesday, April 10, 2024
Consensus, Glaucoma, Conditional sentence, University, Finance, RMB, Risk, Approximation error, Patient, Artificial intelligence, Medical device, National Health Commission, Optometry, Endocrinology, Dementia, Certification, Hyperthyroidism, Ageing, Capital Medical University, Software, MICCAI, Hypertensive retinopathy, Beijing Tongren Hospital, Neurology, Acceleration, Intelligence, Paratriathlon, Hospital, Research, Near-sightedness, Amblyopia, AI, MDR, Strabismus, Skin, AMD, Ranibizumab, Diagnosis, Peking University, Growth, Cardiology, Physical examination, News, Cataract, Diabetic retinopathy, Ophthalmology

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024

Retrieved on: 
Tuesday, April 9, 2024
Device, Intraocular lens, IOL, CDRH, Health equity, Partnership, Patient, SAN, Research, American Academy, Manuscript, MD, ENT, Quality, Safety, FDA, Cataract, Food, Medicine, Dentistry

Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.

Key Points: 
  • Verana Health led the analysis utilizing real-world data from the Academy IRIS Registry – one of the largest specialty society clinical data registries in all of medicine.
  • “The results of this study underscore the transformative potential of high-quality, curated real-world data in generating real-world evidence to enhance treatments and improve patients’ lives,” said Sujay Jadhav, CEO of Verana Health.
  • “We thank the FDA for the opportunity to lead this study, and we extend our appreciation to the Academy for its partnership.
  • Verana Health utilized its clinician-directed and artificial intelligence-enhanced population health data engine, VeraQ ®, to analyze curated, de-identified IRIS Registry data on pediatric cataract surgeries, amplifying the depth and accuracy of the study's insights.

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Level 3, Refractive surgery, ASCRS, BCEC, Patient, Level 2, EDT, Cataract, Society, Lens, LAL, Telescopic sight

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).

Key Points: 
  • The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
  • In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
  • At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
    Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
  • A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
Thursday, April 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.